Evaluating the impact of the Dietary Approaches to Stop Hypertension diet versus a calorie-restricted diet on metabolic dysfunction-associated steatotic liver disease: A meta-analysis of randomized controlled trials

被引：1

作者：

Hasan, Fariha ^{[1
]}

Singh, Avneet ^{[1
]}

Garcia, Alexander ^{[1
]}

Qadri, Syeda Hafsa ^{[2
]}

Sattar, Hina ^{[2
]}

Ali, Rimmel ^{[2
]}

Ali, Hassam ^{[3
]}

Nguyen, Tommy ^{[4
]}

Mohan, Babu P. ^{[5
]}

Contino, Krysta ^{[6
]}

机构：

[1] Cooper Univ Hosp, Dept Internal Med, Camden, NJ USA

[2] Dow Univ Hlth Sci, Dept Internal Med, Karachi, Pakistan

[3] East Carolina Univ, Brody Sch Med, Dept Gastroenterol, Greenville, NC USA

[4] Cooper Univ Hosp, Div Gastroenterol, Camden, NJ USA

[5] Orlando Gastroenterol PA, Gastroenterol & Hepatol, Orlando, FL USA

[6] Rowan Univ, Cooper Univ Hlth Care, Cooper Med Sch, Div Gastroenterol, Camden, NJ USA

来源：

HEPATOLOGY RESEARCH | 2025年 / 55卷 / 04期

关键词：

Dietary Approaches to Stop Hypertension diet; liver fibrosis; meta-analysis; metabolic dysfunction-associated steatotic liver disease; randomized controlled trials; DASH DIET; ADULTS; EPIDEMIOLOGY; MANAGEMENT; WEIGHT; RISK;

D O I：

10.1111/hepr.14155

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Aim: Metabolic dysfunction-associated steatotic liver disease (MASLD) can lead to increased morbidity and mortality. Diets high in refined carbohydrates and saturated fats elevate MASLD risk. The Dietary Approaches to Stop Hypertension (DASH) diet has shown metabolic benefits. This meta-analysis evaluates the impact of the DASH diet on MASLD progression. Methods: A systematic search from 2016 to 2023 across PubMed, Embase, Web of Science, and Cochrane databases was conducted to identify studies reporting on the role of the DASH diet in MASLD. Standard meta-analysis methods were employed using a random-effects model. Heterogeneity was assessed by I2 statistics. Results: We identified five randomized controlled trials meeting inclusion criteria, involving 280 participants (140 in the DASH group and 140 in the control group). Mean ages were approximately 41 years, and the proportions of women were similar between groups. Compared with controls, the DASH diet group had a significantly reduced risk of grade 0 and 1 liver fibrosis (RR 1.21, 95% CI 1.04-1.41, p = 0.01). They also showed lower levels of aspartate aminotransferase (MD -4.81, 95% CI -6.98 to -2.64, p < 0.0001), alanine aminotransferase (MD -10.31, 95% CI -13.82 to -6.80, p < 0.00001), body mass index (MD -0.74, 95% CI -1.45 to -0.03, p = 0.04), and cholesterol-to-high-density lipoprotein ratio (MD -0.40, 95% CI -0.68 to -0.11, p = 0.006). No significant differences were found for weight, waist and hip circumference, total cholesterol, low-density lipoprotein, or high-density lipoprotein levels. Heterogeneity was low for most outcomes (I2 = 0%). Conclusion: Based on our meta-analysis of five randomized controlled trials, the DASH diet may reduce MASLD progression. These findings suggest it could be an effective dietary intervention for MASLD management.

引用

页码：515 / 526

页数：12

共 40 条

[11] Measuring inconsistency in meta-analyses [J].